[
  {
    "ts": null,
    "headline": "Diamond Hill Capital is Crazy About Abbott Laboratories (NYSE:ABT)",
    "summary": "We recently published a list of Diamond Hill Capital Stock Portfolio: Top 10 Stock Picks. In this article, we are going to take a look at where Abbott Laboratories (NYSE:ABT) stands against other top 10 stock picks of Diamond Hill Capital. Heather Brilliant, CFA, serves as CEO for Diamond Hill Capital and joined the firm in 2019, […]",
    "url": "https://finnhub.io/api/news?id=c084f938fc8331f3b8f5fe8e20046d53602d157db731666176081f6cb0ee39bb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742998284,
      "headline": "Diamond Hill Capital is Crazy About Abbott Laboratories (NYSE:ABT)",
      "id": 133457230,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "We recently published a list of Diamond Hill Capital Stock Portfolio: Top 10 Stock Picks. In this article, we are going to take a look at where Abbott Laboratories (NYSE:ABT) stands against other top 10 stock picks of Diamond Hill Capital. Heather Brilliant, CFA, serves as CEO for Diamond Hill Capital and joined the firm in 2019, […]",
      "url": "https://finnhub.io/api/news?id=c084f938fc8331f3b8f5fe8e20046d53602d157db731666176081f6cb0ee39bb"
    }
  },
  {
    "ts": null,
    "headline": "Abbott Hosts Conference Call for First-Quarter Earnings",
    "summary": "Abbott (NYSE: ABT) will announce its first-quarter 2025 financial results on Wednesday, April 16, before the market opens.",
    "url": "https://finnhub.io/api/news?id=d56164b9b2faa1e99a4d6fcfdf1b9c3e6d25aff5bb8e52378cbee528adcc2afa",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742994000,
      "headline": "Abbott Hosts Conference Call for First-Quarter Earnings",
      "id": 133457231,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Abbott (NYSE: ABT) will announce its first-quarter 2025 financial results on Wednesday, April 16, before the market opens.",
      "url": "https://finnhub.io/api/news?id=d56164b9b2faa1e99a4d6fcfdf1b9c3e6d25aff5bb8e52378cbee528adcc2afa"
    }
  },
  {
    "ts": null,
    "headline": "2 Dividend Stocks Defying the Market Dip to Buy for a Lifetime of Passive Income",
    "summary": "AbbVie's shares  dropped off a cliff  in November after it announced a clinical setback for emraclidine, an investigational schizophrenia treatment it got in an $8.7 billion acquisition.  Investors were worried the company spent nearly $9 billion for nothing, which is understandable.",
    "url": "https://finnhub.io/api/news?id=61fd4eaf3f5f7dd6253d719698b576de0bff90fb77dac19641bf03b882b4b2a8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742985000,
      "headline": "2 Dividend Stocks Defying the Market Dip to Buy for a Lifetime of Passive Income",
      "id": 133448346,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "AbbVie's shares  dropped off a cliff  in November after it announced a clinical setback for emraclidine, an investigational schizophrenia treatment it got in an $8.7 billion acquisition.  Investors were worried the company spent nearly $9 billion for nothing, which is understandable.",
      "url": "https://finnhub.io/api/news?id=61fd4eaf3f5f7dd6253d719698b576de0bff90fb77dac19641bf03b882b4b2a8"
    }
  }
]